Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy

Table 3 Association of principal components factors with exercise capacity (pVO₂)

Factor	Overall			Non-diabetic		Diabetic		Interaction p value
Factor	Factor beta	p value	BH p value	Factor beta	p value	Factor beta	p value	Interaction p value
Baseline
1	0.857	2E-7	1E-6	0.669	9E-4	1.58	8E-8	0.012
2	− 0.572	− 0.001	− 0.001	− 1.12	− 0.013	− 0.296	0.088	0.077
3	− 0.596	4E-4	0.001	− 0.351	0.233	− 0.615	0.002	0.443
4	− 1.194	2E-8	3E-7	1.43	5E-5	− 0.906	5E-4	0.222
5	0.623	2E-4	0.001	0.432	0.076	0.822	2E-4	0.234
6	− 0.215	0.198	0.238
7	0.088	0.598	0.653
8	0.773	4E-6	1E-5	0.562	0.065	0.811	2E-5	0.473
9	− 0.314	0.061	0.081
10	0.035	0.837	0.837
11	− 0.457	0.006	0.011	− 0.443	0.099	− 0.359	0.083	0.803
12	0.430	0.011	0.017	0.603	0.034	0.238	0.245	0.288

ISSN: 1475-2840